Lilly's $300M Bet on a Biotech That Doesn't Even Have a Drug in Humans Yet
Eli Lilly just dropped up to $300 million on a two-year-old company with zero drugs in human testing. CrossBridge Bio's dual-payload ADC technology has Big Pharma salivating, and this deal says a lot about where the antibody-drug conjugate arms race is headed.
A Two-Year-Old Company Just Got a Nine-Figure Payday
CrossBridge Bio was founded in 2023. It has zero drugs in clinical trials. Its lead candidate hasn't even been filed with the FDA yet. And Eli Lilly just agreed to buy it for up to $300 million in cash.
That's not a typo. Lilly is paying hundreds of millions of dollars for a Houston-based startup whose entire pipeline lives in the preclinical stage, meaning everything is still being tested in labs and animal models, not people. The deal includes an upfront payment plus a milestone payment tied to hitting a specific development goal, though neither company disclosed exactly how the $300 million splits between the two.
So what could possibly make a three-year-old company with no human data worth that kind of money? The answer lies in a technology that has Big Pharma in a bidding frenzy: antibody-drug conjugates, or ADCs.
The Guided Missile of Cancer Treatment
If you want to understand why Lilly wrote this check, you need to understand ADCs. Think of them as guided missiles for cancer. A traditional chemotherapy drug is like carpet-bombing a city to take out one building: it kills cancer cells, but it also destroys a lot of healthy tissue along the way. An ADC, by contrast, attaches a toxic payload to an antibody that acts like a GPS system, steering the poison directly to cancer cells and (mostly) leaving everything else alone.
The concept has been around for decades, but ADCs have only recently become blockbuster drugs. Pfizer's $43 billion acquisition of Seagen set the benchmark. Since then, pharma companies have been tripping over each other to lock up the next generation of ADC technology.
CrossBridge Bio thinks it has something even better: dual-payload ADCs. Instead of strapping one warhead to the guided missile, CrossBridge straps on two.
Why Two Warheads Beat One
Cancer is annoyingly good at survival. When you hit a tumor with a single drug, some cells inevitably figure out how to resist it. It's like trying to stop a flood with one sandbag; water finds a way around.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Dual-payload ADCs attack this problem by delivering two different toxic agents with completely different mechanisms. If the cancer cells develop resistance to payload A, payload B is already there, hitting them from a different angle. CrossBridge's lead program, CBB-120, combines a topoisomerase-1 inhibitor (a drug that tangles up DNA replication) with an ATR inhibitor (a drug that blocks the cancer cell's ability to repair that DNA damage). It's a one-two punch: break the DNA, then take away the repair kit.
The technology relies on some clever chemistry. CrossBridge uses site-specific conjugation and click chemistry to attach both payloads at precise locations on the antibody, giving each ADC a consistent, controllable ratio of the two drugs. That matters because uniformity in manufacturing is what separates a promising lab result from something you can actually give to patients.
CBB-120 targets a protein called TROP2, which is overexpressed in several solid tumors including triple-negative breast cancer, hormone-positive breast cancer, and colorectal cancer. The company was working toward filing an Investigational New Drug (IND) application with the FDA in 2026, which would have been its ticket to start testing in humans. Now Lilly will take the wheel.
Lilly's Been Building an ADC Arsenal
This isn't Lilly's first shopping spree in the ADC aisle. The Indianapolis pharma giant has been quietly assembling an antibody-drug conjugate portfolio for years.
In 2022, Lilly re-upped its relationship with ImmunoGen through a partnership worth $13 million upfront and up to $1.7 billion in milestone payments. Then in 2023, it acquired two ADC-focused companies in quick succession: Emergence Therapeutics (a German startup) in June, and Mablink Bioscience (a French biotech with a proprietary linker technology called PSARLink) in October.
The CrossBridge deal extends that pattern. Lilly now has ADC capabilities spanning different linker technologies, different payload types, and different conjugation methods. It's building an ADC toolkit, not just buying individual programs.
And the internal pipeline is maturing, too. Lilly already has a breakthrough therapy designation for sofetabart mipitecan, a folate receptor alpha-targeted ADC. CrossBridge's dual-payload platform adds a new dimension: the ability to overcome resistance that might limit those earlier-generation ADCs.
The ADC Gold Rush of 2025-2026
Lilly is far from the only pharma giant throwing money at ADCs. The sector has been in full-on gold rush mode, and the deal sizes keep climbing.
In early 2026, AbbVie licensed rights to RemeGen's RC148 in a deal worth $5.6 billion. Roche paid $570 million for MediLink's B7H3-targeted ADC (YL201) in January 2026. Rewind to 2025, and Boehringer Ingelheim licensed ADC platform company Synaffix's technology for up to $1.3 billion in potential milestone payments and royalties, while Astellas paid over $1.5 billion (including $130 million upfront) for Evopoint Bio's CLDN18.2-targeting ADC.
In that context, Lilly's $300 million for CrossBridge looks almost modest. But there's a reason the price tag is relatively contained: CrossBridge is still preclinical. Lilly is buying potential, not proof.
The Risk Nobody's Talking About
Interestingly, Lilly's Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, has publicly expressed caution about ADC hype. Back in 2023, he noted that new drug classes often generate excessive optimism early on, and ADCs might not be immune to that pattern.
That skepticism apparently hasn't stopped the checkbook from opening. The pace of dealmaking has only accelerated in 2026. It bought Ventyx for over $1 billion in January, Orna for more than $2 billion in February, and Centessa for over $6 billion in March. CrossBridge, at up to $300 million, is April's addition to the collection.
The risk with CrossBridge is straightforward: everything is early-stage. CBB-120 hasn't entered human trials. Dual-payload ADCs are a promising concept backed by compelling preclinical data, but the graveyard of drug development is filled with things that worked beautifully in mice and failed in people. The technology's advantages (better tumor killing, resistance prevention, potentially lower toxicity through targeted delivery) still need to be validated in clinical trials.
And the TROP2 landscape is already crowded. Gilead's Trodelvy and AstraZeneca/Daiichi Sankyo's Datroway are approved TROP2-targeted ADCs. CrossBridge's pitch is that dual payloads can overcome resistance to those existing drugs, but that thesis is, for now, unproven in humans.
What CrossBridge's Backers Are Saying
CrossBridge CEO Michael Torres highlighted the platform's "transformative potential in oncology" and expressed pride in the company's rapid progress since its 2023 founding. CE-Ventures, an early investor, was equally enthusiastic; Deputy CEO Tushar Singhvi called it a "differentiated platform" and praised Lilly as the right partner to advance it.
The company's technology originated in the lab of Kyoji Tsuchikama at UTHealth Houston, and its funding history tells the story of a scrappy academic spinout: a $10 million seed round in November 2024, a $2.6 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) in May 2024, and a $15 million CPRIT grant in November 2025.
From seed funding to a $300 million exit in roughly two years is, by any measure, an exceptional return for early investors. It also reflects how insatiable Big Pharma's appetite for ADC technology has become.
The Bigger Picture
Lilly's acquisition of CrossBridge isn't really about one preclinical program. It's about positioning. The ADC field is evolving from first-generation single-payload designs toward more sophisticated platforms: dual payloads, novel linkers, new conjugation chemistries. Companies that can deliver multiple mechanisms of action in a single molecule will have a structural advantage as resistance to existing ADCs inevitably emerges.
Lilly is essentially buying insurance against the future. If single-payload ADCs hit a wall (and cancer drugs historically do), dual-payload technology could be the next chapter. At $300 million for an entire platform, Lilly is paying a fraction of what AbbVie spent on its RemeGen deal or what Astellas paid for Evopoint.
The accounting treatment hasn't been determined yet; Lilly will decide whether to classify this as a business combination or an asset acquisition. That distinction matters for how the costs flow through financial statements, but the strategic logic is the same either way.
For the broader ADC space, this deal sends a clear signal. The M&A frenzy isn't cooling off. If anything, acquirers are reaching earlier in the development cycle, willing to pay nine figures for preclinical platforms they believe in. The bet isn't just on CrossBridge. It's on the idea that the ADC revolution is still in its early innings, and the best technology hasn't been built yet.
Lilly thinks it just bought the blueprint.
Funding & Financings
4 min read
The Protein Company That Tripled Revenue Wants a Billion-Dollar Valuation
A protein detection company you've probably never heard of just tripled its revenue and is asking Wall Street for a billion-dollar valuation. Alamar Biosciences is betting that proteins, not just DNA, hold the key to finding diseases early.
